Alice Huertas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1698903/publications.pdf Version: 2024-02-01

ALICE HUEDTAS

#	Article	IF	CITATIONS
1	Inflammation in Pulmonary Arterial Hypertension. Chest, 2012, 141, 210-221.	0.8	333
2	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. European Respiratory Journal, 2020, 56, 2001634.	6.7	284
3	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	8.2	208
4	Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscle–Like Cells in Pulmonary Hypertension. Circulation, 2014, 129, 1586-1597.	1.6	178
5	C-Kit–Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 116-123.	5.6	176
6	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. European Respiratory Review, 2013, 22, 543-551.	7.1	172
7	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 983-997.	5.6	144
8	Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1332-1340.	1.6	141
9	New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Chest, 2015, 147, 529-537.	0.8	140
10	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	6.7	136
11	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1956-1970.	8.2	125
12	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 895-904.	6.7	110
13	Activation of TNFR1 ectodomain shedding by mitochondrial Ca2+ determines the severity of inflammation in mouse lung microvessels. Journal of Clinical Investigation, 2011, 121, 1986-1999.	8.2	89
14	A Critical Role for p130 ^{Cas} in the Progression of Pulmonary Hypertension in Humans and Rodents. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 666-676.	5.6	85
15	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation Research, 2019, 124, 846-855.	4.5	81
16	COPD: a multifactorial systemic disease. Therapeutic Advances in Respiratory Disease, 2011, 5, 217-224.	2.6	78
17	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovascular Research, 2020, 116, 885-893.	3.8	70
18	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest, 2016, 149, 1482-1493.	0.8	63

ALICE HUERTAS

#	Article	IF	CITATIONS
19	Leptin signalling system as a target for pulmonary arterial hypertension therapy. European Respiratory Journal, 2015, 45, 1066-1080.	6.7	62
20	Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. Journal of Applied Physiology, 2010, 109, 60-67.	2.5	58
21	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196.	5.6	54
22	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovascular Research, 2020, 116, 686-697.	3.8	54
23	Dasatinib increases endothelial permeability leading to pleural effusion. European Respiratory Journal, 2018, 51, 1701096.	6.7	50
24	Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. Respiratory Physiology and Neurobiology, 2010, 170, 23-31.	1.6	47
25	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 766-782.	2.4	44
26	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.8	43
27	Pulmonary veno-occlusive disease: advances in clinical management and treatments. Expert Review of Respiratory Medicine, 2011, 5, 217-231.	2.5	41
28	Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332.	6.7	28
29	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Chest, 2022, 161, 219-231.	0.8	26
30	Platelets Enhance Endothelial Adhesiveness in High Tidal Volume Ventilation. American Journal of Respiratory Cell and Molecular Biology, 2008, 39, 569-575.	2.9	24
31	Erythrocytes Induce Proinflammatory Endothelial Activation in Hypoxia. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 78-86.	2.9	23
32	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular Research, 2021, 117, 1391-1401.	3.8	23
33	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2019, 33, 3670-3679.	0.5	22
34	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272.	6.7	21
35	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. Journal of Medicinal Chemistry, 2018, 61, 2725-2736.	6.4	20
36	The Thousand Faces of Leptin in the Lung. Chest, 2021, 159, 239-248.	0.8	18

ALICE HUERTAS

#	Article	IF	CITATIONS
37	New targets for pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2017, 23, 377-385.	2.6	16
38	Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1587-1598.	3.3	15
39	Platelets induce endothelial tissue factor expression in a mouse model of acid-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L1209-L1220.	2.9	13
40	Circulating fibrocytes and pulmonary arterial hypertension. European Respiratory Journal, 2012, 39, 210-212.	6.7	8
41	Circulating CD34+ Cells Are Decreased in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 537-538.	3.5	7
42	A study of magnesium deficiency in human and experimental pulmonary hypertension. Magnesium Research, 2012, 25, 21-27.	0.5	2
43	Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model. , 2018, , .		1
44	Red blood cellâ€induced proinflammatory lung endothelial signaling in hypoxia. FASEB Journal, 2009, 23, 1023.4.	0.5	0
45	Airway acid instillation promotes procoagulant lung endothelial mechanisms in mouse. FASEB Journal, 2009, 23, 1023.5.	0.5	Ο
46	Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. Pancreatic Islet Biology, 2015, , 241-256.	0.3	0
47	Uric acid contributes to the progression of pulmonary hypertension in rodents and humans. , 2018, , .		0